🚨Trade Alert 🚨 TLSA

🚨Trade Alert 🚨 TLSA͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ Trading at around $1, TLSA is a biotech company that isn’t getting nearly enough attention for the monstrous upside it could see ahead…. Greetings All, The biotech space holds promise for rag-to-riches stories as companies develop groundbreaking drugs to help people. Tiziana Life Sciences Ltd. is a biotech company trading on the NASDAQ that could soon catch major Wall Street attention for what could turn into a “wonder drug” that they are developing. This is the kind of drug that could really shake things up in the trillion-dollar healthcare space! Trading under the ticker symbol TLSA, the stock holds a 12-month price forecast of $3.06, an incredible 200%+ increase from its current price. The company’s own interim CEO and Chairman Gabriele Cerrone has recently purchased 8,000 common shares at $0.89 per share, bringing his total holding to 38,701,237 common shares. Insider ownership stands at a staggering 41% indicating that the company’s team has complete faith in their lead candidate Foralumab turning it into the next biotech darling. Foralumab is the world’s only fully human, anti-CD3 mAb in clinical development! It is gaining recognition across the scientific community with features in medical media that include Pharmacy Times. It was recently highlighted positively in a Forbes article that can be read [HERE.](~/AASl5QA~/RgRmBU3FP0TYaHR0cHM6Ly93d3cuZm9yYmVzLmNvbS9zaXRlcy93aWxsaWFtaGFzZWx0aW5lLzIwMjMvMDMvMTYvbmV3LXQtY2VsbC1hbnRpYm9keS10cmVhdG1lbnQtaW1wcm92ZXMtb3V0Y29tZXMtZm9yLWNvdmlkLXBhdGllbnRzLz9zaD1kMjg4NjM1NjcwZjkmX2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNmJhSWZ1cXJZU2pybUl3SU5PanBPRjk3eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMVwNzcGNCCmQixcgiZA5EqqJSG3RyaXN0cmFtYmFsZHdpbjg3QGdtYWlsLmNvbVgEAAXhsQ~~) What else makes TLSA stand out? The company is developing transformational formulation technologies, enabling to switch from traditional routes to alternative routes of immunotherapy to facilitate local site of action. If the company succeeds in these alternative routes of immunotherapies, it has the potential to change the way immunotherapies are currently conducted! In other words, TLSA could disrupt the immunotherapies market significantly…. The company’s clinical pipeline is aiming to help central nervous system (CNS) diseases and includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. “We look forward to leveraging the exciting clinical and preclinical results from our very promising formulation of intranasal foralumab that we have generated so far in CNS-based autoimmune diseases to guide our pipeline investment. We aim to become a leading company pioneering intranasal therapies for CNS-based diseases.” - Gabriele Cerrone, executive chairman and interim CEO of Tiziana. Proactive research analyst Robin Davison recently published a 2023 Clinical Outlook for TLSA and remarked that it is ["moving forward quite nicely."](~/AASl5QA~/RgRmBU3FP0TDaHR0cHM6Ly9uZXdzZGlyZWN0LmNvbS9uZXdzL3Byb2FjdGl2ZS1yZXNlYXJjaC1hbmFseXN0LXNheXMtdGl6aWFuYS1saWZlLXNjaWVuY2VzLW1vdmluZy1mb3J3YXJkLXF1aXRlLW5pY2VseS01NDY3OTIxNzY_X2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNmJhSWZ1cXJZU2pybUl3SU5PanBPRjk3eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMVwNzcGNCCmQixcgiZA5EqqJSG3RyaXN0cmFtYmFsZHdpbjg3QGdtYWlsLmNvbVgEAAXhsQ~~) AND… the company has plenty of cash on hand to continue its clinical studies and to move closer to getting its drug candidates commercialized and into markets. TLSA ended the period with [$26.5m cash](~/AASl5QA~/RgRmBU3FP0SbaHR0cHM6Ly9maW5hbmNlLnlhaG9vLmNvbS9uZXdzL3RpemlhbmEtbGlmZS1zY2llbmNlcy1sdGQtdGl6aWFuYS0yMjAwMDAzMjEuaHRtbD9fa3g9Xy1IU3BvMnk5bERXSmU1Zks2eDM2YmFJZnVxcllTanJtSXdJTk9qcE9GOTd5cDVfbzM3d05vSU16TlQwbDJEWC5UYTlyaExXA3NwY0IKZCLFyCJkDkSqolIbdHJpc3RyYW1iYWxkd2luODdAZ21haWwuY29tWAQABeGx) as at 30 June 2022. There could be phenomenal growth potential here as Wall Street continues to learn about TLSA’s lead immunotherapeutic candidate Foralumab! Company Overview Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Its technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications. The company’s mission is to bring breakthrough therapies to patients with the aim of treating Secondary Progressive Multiple Sclerosis, ALS, Alzheimer's, and other CNS indications. Crohn's Disease, lung diseases and optimizing health outcomes. Clinical Candidates TLSA’s major clinical assets are supported by extensive worldwide issued patents and pending patent applications covering composition of matter, formulation technologies, manufacturing processes and disease indications. - Foralumab - Foralumab is a fully human anti-CD3 monoclonal antibody (mAb) for treatment of Crohn’ s Disease and neurodegenerative indications. - Anti IL-6 Receptor mAb (IL-6R:TZLS-501) - The company is developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6 as a potential treatment for lung diseases. - Milciclib - Milciclib is the Company’s clinical candidate for the treatment in cancer indications. The company is exploring the combination of milciclib and gemcitibine in NSCLC patients with pan KRAS+ mutations. Lead Drug Candidate - Foralumab The company’s lead candidate, intranasal foralumab, is the only fully human anti-CD3 mAb, and has demonstrated a favorable safety profile and clinical response in patients in studies to date. This unique intranasal monoclonal antibody is currently in clinical development to treat multiple sclerosis (MS) and a range of other neurodegenerative diseases. TLSA isn’t in R&D… the company is already in the clinical stage and has completed two pivotal Phase 1 clinical trials with foralumab: - One for progressive MS indication with nasal administration - One for Crohn’s disease indication, with enteric-coated capsules administered orally Crohn’s disease affects between 400,000 and 600,000 people in North America. Current estimates for Northern Europe have ranged from 27–48 people per 100,000. Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease affecting approximately 400,000 people in the United States and 2.1 million people worldwide. The company also completed a Phase 2 trial treating mild to moderate non-hospitalized COVID-19 patients in Brazil with intranasal foralumab with positive results. Currently, six secondary progressive MS patients are being treated at Brigham and Women’s Hospital, Boston MA, with intranasal foralumab under Expanded Access INDs with signs of clinical benefit. EA1 has completed Twenty months of treatment and EA2 has completed Thirteen months. Investigators under Tiziana’s umbrella have performed additional work using the anti-CD3 foralumab in Alzheimer’s disease (AD), Amyotrophic Lateral Sclerosis (ALS) and an undisclosed rare pediatric disease where there are no other treatments showing that there may be a benefit to patients. Others have performed studies showing that anti-CD3 may mitigate the severity of diabetes, arthritis, inflammatory bowel disease, and lupus. Foralumab has demonstrated the ability to activate regulatory T cells that systemically circulate to elicit targeted immunomodulation providing therapeutic benefit to patients. Tiziana has additionally submitted a patent application on potential use of Foralumab, to improve success of chimeric antigen receptor T cells (CAR-T) therapy for cancer and other human diseases. The patent application covers inventions related to improving CAR-T expansion and/or survival. SPMS: A Top Priority Foralumab is designed to treat patients suffering from MS, reducing inflammatory responses which are brought on by the immune system In January TLSA reported that the second patient (“EA2”) with non-active secondary progressive multiple sclerosis (SPMS) receiving intranasal foralumab has shown additional clinical improvements since their last reported improvement in September 2022. The improvements were measured by the Expanded Disability Status Scale (EDSS), a U.S. Food and Drug Administration (FDA) - recognized standard clinical outcome assessment that is a measure of neural network functioning, rating different measures from 1 to 10 (disability increasing with higher scores). Before foralumab treatment, EA2’s non-active SPMS disability had progressed and EDSS worsened from 3.5 in 2018 to 6.0 in 2021 despite ocrelizumab therapy. Ocrelizumab was discontinued in 2021. At this point, EA2 required a cane to walk 100 meters. EA2 was subsequently enrolled in the intranasal foralumab Expanded Access program in January 2022. In September 2022, 8 months after starting treatment with nasal foralumab, EA2 was able to walk 100 meters WITHOUT a cane!! EDSS score improved from 6.0 to 5.5. EA2’s pyramidal score remained stable during this time. In December 2022, 11 months after starting treatment with intranasal foralumab, EA2 was able to walk 200 meters without a cane, resulting in an even greater improvement in EDSS; with EDSS falling from a score of 5.5 to 5.0. EA2’s pyramidal score continued to remain stable. “Six patients are currently enrolled and are being followed in our intranasal foralumab program. EA2’s clinical improvement justifies Tiziana’s decision to make intranasal foralumab for non-active SPMS our top priority.” - Gabriele Cerrone, Executive Chairman and interim CEO of Tiziana. SPMS represents an advanced stage of multiple sclerosis with few treatment options and creates a severe burden on patients. For there to be a 1.0 EDSS improvement in patient EA2 following treatment with intranasal foralumab…. this is truly ground-breaking! In summary… Biotech is a red-hot industry with diligent eyes on the arena watching out for the next big thing. The potential for substantial returns makes companies in the space perpetually attractive. Identifying companies with the best chances of developing breakthrough drugs or therapies is paramount to success and TLSA looks like one of them! The company is aiming to bring to market a unique drug candidate that could significantly help millions of people. There’s only one reason why insiders would be loading up and that’s because they believe their company is headed higher… TLSA is already in the clinical stage and has sufficient cash reserves to perform Phase 2 MS trial. The company plans to use non-dilutive funding for Alzheimer’s Disease, ALS, and T1D studies. The cogs are in motion and Tiziana Life Sciences Ltd. (NASDAQ: TLSA) could be heading toward an FDA green light in its future. Now is the time to have the company high on your radar! Copyright 2022 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in TLSA. We have been currently compensated one hundred seventy-five thousand Dollars Cash ($175,000) via bank wire transfer from a third-party IA Media, LLC for a 1 Day Marketing Program regarding TLSA with a start date of 3/28/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. No longer want to receive these emails? [Unsubscribe](~/AASl5QA~/RgRmBU3FP0SoaHR0cHM6Ly9tYW5hZ2Uua21haWwtbGlzdHMuY29tL3N1YnNjcmlwdGlvbnMvdW5zdWJzY3JpYmU_YT1UYTlyaEwmYz0wMUdBUDhESDJQN0VCQ0RNSlJUNEs2MjIwNCZrPWIyNTkwYjFhMzYyOGZiMmZjOTllZjdhMDZlMWRmYjVjJm09MDFHV0pQUEYxTTM4NVE1UDhCV1FNWDE5Vk0mcj1XTkZnd3ptVwNzcGNCCmQixcgiZA5EqqJSG3RyaXN0cmFtYmFsZHdpbjg3QGdtYWlsLmNvbVgEAAXhsQ~~). Small Caps Daily 1334 Northampton St Easton, PA 18042